Our expansion plans

Our continued growth means greater integration for your programs, with end-to-end CDMO services spanning API synthesis to injectable and liquid oral manufacturing.

Our new facility: Expanding beyond API

We are in an advanced stage of commissioning of our new facility. Set for completion in 2026, it’s designed to broaden our service offering beyond API manufacturing to include:

• Dosage form manufacturing capabilities, including sterile injectables and oral liquids.
• Enhanced formulation development capacity.
• State-of-the-art cleanroom environment and automation to manufacture aseptic, terminally sterilized and lyophilized products.
• Microbiology and analytical laboratories supporting formulation and release testing.
• Expanded temperature-controlled storage
• Upgraded warehousing infrastructure.

With an integrated platform on a single site, we can ensure end-to-end control and efficiency from API synthesis through finished dosage production.